To include your compound in the COVID-19 Resource Center, submit it here.

Ponesimod: Phase IIb data

A double-blind, international Phase IIb trial in 464 patients with RRMS showed that once-daily oral ponesimod met the primary endpoint of significantly reducing the cumulative number of

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE